Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Can Respir J. 2013 May-Jun;20(3):180-2.

Biomarkers in airway diseases.

Author information

  • 1Critical Care Medicine Department, National Institute of Health, Bethesda, Maryland 20892, USA. janice.leung@nih.gov

Abstract

The inherent limitations of spirometry and clinical history have prompted clinicians and scientists to search for surrogate markers of airway diseases. Although few biomarkers have been widely accepted into the clinical armamentarium, the authors explore three sources of biomarkers that have shown promise as indicators of disease severity and treatment response. In asthma, exhaled nitric oxide measurements can predict steroid responsiveness and sputum eosinophil counts have been used to titrate anti-inflammatory therapies. In chronic obstructive pulmonary disease, inflammatory plasma biomarkers, such as fibrinogen, club cell secretory protein-16 and surfactant protein D, can denote greater severity and predict the risk of exacerbations. While the multitude of disease phenotypes in respiratory medicine make biomarker development especially challenging, these three may soon play key roles in the diagnosis and management of airway diseases.

PMID:
23762888
[PubMed - indexed for MEDLINE]
PMCID:
PMC3814266
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Pulsus Group Inc Icon for PubMed Central
    Loading ...
    Write to the Help Desk